Spaulding Clinical Awarded Multiple Phase III Core ECG Lab Studies

June 14, 2010 – WEST BEND, WI. – Spaulding Clinical Research, a Phase I Unit and Core ECG Lab announced today that it has been awarded its first Phase III centralized cardiac safety studies from an international biotech company. The award includes two studies with approximately 100 sites in multiple countries. Both studies require immediate start-up of ECG services.

Spaulding Clinical began conducting Phase I studies in 2009, and to date has managed numerous studies in their Phase I Unit that include centralized cardiac safety, but these are the first two studies that encompass a late stage, multi-site service offering.

Dr. Jay Mason, Spaulding Clinical CMO, stated, “Spaulding was awarded these Phase III contracts very shortly after its announcement of Phase III Core ECG Lab capabilities, because of the ability to respond to an unusually urgent time line at a unusually competitive price – both the result of our system’s simplicity and efficiency, and byproducts of the advanced, integrative technology we are using. Because FDA and Pharma are focusing progressively greater attention on the cardiac safety of new drugs, the role of electocardiography has increased substantially, and, along with it, the need for ECG information systems that cost less, are easier to use and provide more data of higher quality. The Spaulding ECG Core Laboratory is a novel ECG information system that has fully discarded the expensive, inefficient methods in use today and replaced them with a purpose-built solution that is naturally economical, simple to deploy and much more informative.”

Spaulding Clinical is launching its new business unit, ECG Information Solutions at the DIA meeting June 13 -16. Utilizing a novel approach, Spaulding Clinical will educate the industry on the methodology behind its new business unit, which is driven by a proprietary palm-sized ECG acquisition device, over the coming months.

Spaulding Clinical is a Phase I Clinical Research Unit and Electrocardiography Core Lab located in West Bend, Wisconsin offering a full range of services including TQT studies, first-in-human studies, multiple rising dose, Bioavailability and bioequivalence, drug interaction, food effect studies, PK/PD characterization, and data collection and management. Spaulding Clinical also offers a full suite of Electrocardiography Core Lab and over-reading services with state-of-the-art technology and cardiac expertise.

About Spaulding Clinical
Spaulding Clinical (www.spauldingclinical.com) is a Phase I Clinical Research Unit and Electrocardiography Core Lab located in West Bend, Wisconsin offering a full range of services including TQT studies, first-in-human studies, multiple rising dose, bioavailability and bioequivalence, drug interaction, food effect studies, PK/PD characterization, and data collection and management. Spaulding Clinical also offers a full suite of Electrocardiography Core Lab and over-reading services with state of-the- art technology and cardiac expertise.

Spaulding Clinical Contact:
Amanda Baltz
Sr. Director, Business Operations and Development
262.306.3324
[email protected]